INC Research (NASDAQ:SYNH) was downgraded by equities researchers at TheStreet from a “b-” rating to a “c” rating in a report released on Monday, December 18th.
Other research analysts also recently issued research reports about the stock. Zacks Investment Research upgraded shares of INC Research from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research report on Wednesday, September 27th. BidaskClub upgraded shares of INC Research from a “sell” rating to a “hold” rating in a research report on Thursday, December 7th. Mizuho began coverage on shares of INC Research in a research report on Thursday, September 21st. They set a “neutral” rating and a $57.00 price target on the stock. Barclays began coverage on shares of INC Research in a research report on Monday, December 11th. They set an “equal weight” rating and a $40.00 price target on the stock. Finally, Jefferies Group upgraded shares of INC Research from a “hold” rating to a “buy” rating and upped their target price for the company from $62.50 to $69.00 in a research report on Monday, October 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the stock. INC Research has a consensus rating of “Buy” and an average target price of $50.78.
Shares of INC Research (SYNH) traded up $0.10 during trading on Monday, reaching $42.20. 589,329 shares of the company’s stock traded hands, compared to its average volume of 1,149,980. INC Research has a 12-month low of $33.60 and a 12-month high of $61.10. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.27 and a quick ratio of 1.27. The company has a market cap of $8,700.00, a price-to-earnings ratio of -74.04, a PEG ratio of 1.25 and a beta of 1.09.
INC Research (NASDAQ:SYNH) last issued its earnings results on Thursday, November 9th. The company reported $0.54 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.63 by ($0.09). INC Research had a negative net margin of 18.00% and a negative return on equity of 35.13%. The firm had revenue of $592.21 million during the quarter, compared to analyst estimates of $604.95 million. During the same quarter in the prior year, the firm posted $0.64 EPS. The firm’s revenue for the quarter was up 128.2% on a year-over-year basis. sell-side analysts forecast that INC Research will post 2.15 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/11/inc-research-incr-downgraded-by-thestreet-to-c.html.
INC Research Company Profile
Syneos Health, Inc, formerly INC Research Holdings, Inc, is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
Receive News & Ratings for INC Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research and related companies with MarketBeat.com's FREE daily email newsletter.